Small molecule · Inhibitor of ribonucleotide reductase and DNA · developed by Lilly
ApprovedFDA, May 1996
3Registered trials
What is Gemcitabine?
Gemcitabine is a nucleoside metabolic inhibitor that is converted intracellularly to active metabolites. The diphosphate form inhibits ribonucleotide reductase, reducing deoxynucleotide pools, while the triphosphate form incorporates into DNA and causes strand termination, triggering apoptosis.
Summary written with AI from the sources listed at the end of this page.
Advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy (in combination with carboplatin)
Metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy (in combination with paclitaxel)
Non-small cell lung cancer (in combination with cisplatin)
Locally advanced or metastatic pancreatic adenocarcinoma
Advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy (in combination with carboplatin)
Metastatic breast cancer after failure of prior anthracycline-containing adjuvant chemotherapy (in combination with paclitaxel)
Non-small cell lung cancer (in combination with cisplatin)
Locally advanced or metastatic pancreatic adenocarcinoma
From the indications section of the FDA label (version of Jul 27, 2026). Read the full label for the exact wording, limitations and safety information.
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.